Vanderbilt Institute for Global Health, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Vanderbilt Institute for Global Health, Vanderbilt University Medical Center, Nashville, Tennessee, USA; Department of Health Policy, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Kidney Int. 2021 Jul;100(1):146-154. doi: 10.1016/j.kint.2021.03.038. Epub 2021 Apr 24.
HIV-positive adults are at risk for various kidney diseases, and apolipoprotein 1 (APOL1) high-risk genotypes increase this risk. This study aimed to determine the prevalence and ethnic distribution of APOL1 risk genotypes among a cohort of HIV-positive Nigerian adults and explore the relationship between APOL1 risk variant status with albuminuria and estimated glomerular filtration rate (eGFR). We conducted a cross-sectional study among 2 458 persons living with HIV who attended an HIV clinic in northern Nigeria and had received antiretroviral therapy for a minimum of six months. We collected two urine samples four-eight weeks apart to measure albumin excretion, and blood samples to measure eGFR and determine APOL1 genotype. The frequency of APOL1 high-risk genotype was 6.2%, which varied by ethnic group: Hausa/Fulani (2.1%), Igbo (49.1%), and Yoruba (14.5%). The prevalence of microalbuminuria (urine/albumin creatinine ratio 30- 300 mg/g) was 37%, and prevalence of macroalbuminuria (urine/albumin creatinine ratio over 300 mg/g) was 3%. The odds of microalbuminuria and macroalbuminuria were higher for participants with the APOL1 high-risk genotype compared to those carrying the low-risk genotype ([adjusted odds ratio 1.97, 95% confidence interval 1.37-2.82] and [3.96, 1.95-8.02] respectively). APOL1 high-risk genotype participants were at higher risk of having both an eGFR under 60 ml/min/1.73m and urine/albumin creatinine ratio over 300 mg/g (5.56, 1.57-19.69). Thus, we found a high proportion of HIV-positive, antiretroviral therapy-experienced, and largely virologically suppressed adults had microalbuminuria. Hence, although the high-risk APOL1 genotype was less prevalent than expected, it was strongly associated with some level of albuminuria.
HIV 阳性成年人易患各种肾脏疾病,载脂蛋白 1(APOL1)高危基因型会增加这种风险。本研究旨在确定在尼日利亚 HIV 阳性成年人队列中,APOL1 风险基因型的流行率和种族分布,并探讨 APOL1 风险变异体状态与白蛋白尿和估计肾小球滤过率(eGFR)之间的关系。我们对在尼日利亚北部的一家 HIV 诊所接受抗逆转录病毒治疗至少 6 个月的 2458 名 HIV 感染者进行了一项横断面研究。我们收集了相隔 4-8 周的两份尿液样本以测量白蛋白排泄量,并采集了血液样本以测量 eGFR 和确定 APOL1 基因型。高危基因型的频率为 6.2%,按种族划分:豪萨/富拉尼(2.1%)、伊博(49.1%)和约鲁巴(14.5%)。微量白蛋白尿(尿白蛋白肌酐比 30-300mg/g)的患病率为 37%,大量白蛋白尿(尿白蛋白肌酐比>300mg/g)的患病率为 3%。与携带低危基因型的参与者相比,携带高危基因型的参与者发生微量白蛋白尿和大量白蛋白尿的几率更高(调整后的优势比 1.97,95%置信区间 1.37-2.82]和[3.96,1.95-8.02])。高危基因型的参与者发生 eGFR<60ml/min/1.73m 和尿白蛋白肌酐比>300mg/g 的风险更高(5.56,1.57-19.69)。因此,我们发现,相当一部分接受过抗逆转录病毒治疗且病毒学抑制良好的 HIV 阳性成年人存在微量白蛋白尿。因此,尽管高危 APOL1 基因型的流行率低于预期,但它与一定程度的白蛋白尿密切相关。